Showing results (101-110 of 127) with videos related to

Sort By:
Pageof 13
Inflammatory Bowel Diseases|June 1, 2001
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot studyB E Sands, W J Tremaine, W J Sandborn, et al.
Gut|August 6, 1998
Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic roleJ F Quinton, B Sendid, D Reumaux, et al.
Gastroenterology|December 2, 1999
An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's diseaseE A Vasiliauskas, L Y Kam, M T Abreu-Martin, et al.
The American Journal of Gastroenterology|December 1, 1995
Pouchitis disease course after orthotopic liver transplantation in patients with primary sclerosing cholangitis and an ileal pouch-anal anastomosisB J Zins, W J Sandborn, C R Penna, et al.
Alimentary Pharmacology & Therapeutics|July 13, 2012
Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolismD Q Shih, M Nguyen, L Zheng, et al.
Inflammatory Bowel Diseases|December 1, 1999
A genome-wide search identifies potential new susceptibility loci for Crohn's diseaseY Ma, J D Ohmen, Z Li, et al.
Gastroenterology|June 1, 1996
Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroupE A Vasiliauskas, S E Plevy, C J Landers, et al.
Gastroenterology|March 1, 1993
Distinct associations of HLA class II genes with inflammatory bowel diseaseH Toyoda, S J Wang, H Y Yang, et al.
Alimentary Pharmacology & Therapeutics|April 4, 2001
Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's diseaseF Cornillie, D Shealy, G D'Haens, et al.
Mucosal Immunology|May 23, 2014
Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosisD Q Shih, L Zheng, X Zhang, et al.
Pageof 13